EUROPE Winner... JOHN HAWKINS
CEO of All in One Medical United Kingdom
About All in One Medical The quest to eradicate hospital- acquired infections across the world is one step closer thanks to innovative product development by All in One Medical.
In the early 2000’s, DCCL, now trading as All in One Medical, recognised a growing and urgent need to combat the spread of hospital-acquired infections across the world.
This was, and still is a global public health issue. Hospitals in the UK face fines if they fail to meet
Product application
In 2003 All in One Medical patented biocidal protected hospital curtains, and a hook mechanism for quick release to speed up changing of bed bays and eliminate cross contamination of infections.
Multiple teaching hospitals adopted the new designs, costing less than the products they were currently using. This delivered considerable savings to the NHS at the same time.
The company also recognised that patients need safe care whilst in a vulnerable state in hospital. Their products help to protect patients and their families from the risk of cross infection. The typical patient curtain harbours many potentially infectious pathogens such as MRSA, C. diff and VRE. All of these can cross infect patients as they, or their carers, simply pull the curtains for privacy.
The All in One Medical curtains do
not harbour pathogens. The Fantex coating kills them stone dead. Thus an increasing number of top teaching hospitals between the UK and Australia are buying their curtains and window blinds from All in One Medical.
The product range in the health sector has developed further and now extends beyond hospital bed curtains and blinds to soft furnishings, mattress covers and cleaning products.
John Hawkins - A man with
minimum standards of hygiene or if cross infection rates are unacceptably high.
All in One Medical researched and developed uses for the chemical compound known as Fantex, remarkable for its microbial protection properties.
And by applying the chemical to produce a series of biocidal fabrics the results were staggering. With the fabrics attracting, capturing and killing 99.999% of germs, the possibility
of using them to protect patients within hospitals became a reality.
In fact, Fantex is proven to be effective in eradicating known pathogens, including the SARS coronavirus, Norovirus, MRSA and C. diff. It is also highly effective against E. coli, VRE, P. aeruginosa and Candida albicans.
And the beauty of the product is that it offers continued protection throughout its life, continuing antibacterial action even after repeated contamination.
John Hawkins, CEO of All in One Medical, was a senior partner in Accenture, before moving on to All in One Medical 4 years ago.
In his previous roles, he has been a strategic thinker, a visionary, and a manager of change and transformation. It is these qualities that he brings to All in One Medical, spearheading considerable growth of the company.
John is the driving force behind new product development, keen to capitalise on the immense potential that Fantex holds within and beyond the healthcare sector.
And he played an integral role in the key decision to move manufacture from China to its base
Investment
Earlier this year, growth capital investors Beringea invested £3m in DCCL in recognition of the growth prospects for the company, and the work and vision that John has brought to the business.
They recognise that there are a number of opportunities to develop the product range outside of the healthcare sector, which in itself
FINANCE MONTHLY CEO AWARDS 2014
John Hawkins, CEO of All in One Medical 38
www.finance-monthly.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86